Fisher CMCerebral thromboangiitis obliterans (including a critical review of the literature) . Medicine36:169-209, 1957.
13.
Wessler S., Ming SC, Gurewich V., et al. A critical evaluation of thromboangiitis obliterans. N Engl J Med262:1149-1160, 1960 .
14.
Barker NWThe case for retention of the diagnostic category "thromboangiitis obliterans ." Circulation25:1-4, 1962.
15.
McPherson JR , Juergens JL, Gifford RW Jr.Thromboangiitis obliterans and arteriosclerosis obliterans. Clinical and prognostic differences. Ann Intern Med59:288-296, 1963.
16.
De Takatas G.Classification of Buerger's disease. N Engl J Med263:412, 1960.
17.
Brown H., Selwood RA, Harrison CV, et al. Thromboangiitis obliterans. Br J Surg56:59-63, 1969.
18.
Eadie DGA , Mann CV, Smith PGBuerger's disease, a clinical and pathological reexamination. Br J Surg55:452-456, 1968.
19.
Zannini G., Cotrufo M.Epidemiological, angiographic and clinical aspects of Buerger's disease . J Cardiovasc Surg14:17-20, 1973.
20.
Richards RLThrombo-angiitis obliterans, clinical diagnosis and classification of cases. Br Med J1:478-481, 1953.
21.
Richards RLThrombo-angiitis obliterans (Buerger's disease) in the west of Scotland. Scott Med J17:50-56, 1972.
22.
Morris-Jones W., Jones CDP.Buerger's disease in women. A report of a case and a review of the literature. Angiology24:675-690, 1973.
23.
Mozes M., Cahansky G., Deutsch V., et al. The association of atherosclerosis and Buerger's disease: A clinical and radiological study. J Cardiovasc Surg11:52-59, 1970.
24.
McLaughlin GA, Helsby CR, Evans CC, et al. Association of HLA-A9 and HLA-B5 with Buerger's disease. Br Med J2:1165-1166, 1976.
25.
Uza G., Vlaich R.Serum zinc and copper in patients with atherosclerosis and thromboangiitis obliterans. Biol Trace Element Res20:197-206, 1989.
26.
Szendro G., Golcman L., Cristal N.Study of the factors affecting blood viscosity in patients with thromboangiitis obliterans. A preliminary report. J Vasc Surg7:759-762, 1988.
27.
Matsushima M., Shionoya S., Matsumoto T.Urinary cotinine measurements in patients with Buerger's disease-Effect of acute and passive smoking on the disease process. J Vasc Surg14:53-58, 1991.
Goldsmith GA , Brown GEPain in thrombo-angiitis obliterans: A clinical study of 100 consecutive cases. Am J Med Sci189:819-833, 1935.
30.
Hirai M., Shionoya S.Arterial obstrction of the upper limb in Buerger's disease: Its incidence and primary lesion. Br J Surg66:124-128, 1979.
31.
Allen EVThromboangiitis obliterans. Methods of diagnosis of chronic occlusive arterial lesions distal to the wrist with illustrative cases. Am J Med Sci178:237-244, 1929.
Lie JTDiagnostic histopathology of major systemic and pulmonary vasculitic syndromes . Rheum Dis Clin North Am16:269-292, 1990.
34.
Shionoya S.Buerger's Disease. Pathology, Diagnosis and Treatment. Nagoya: University of Nagoya Press, 1990.
35.
Adar R.Buerger's disease—The need for diagnostic criteria. Surgery76:848, 1974.
36.
Adar R., Papa MZThe definition of Buerger's disease. World J Surg8:423, 1984.
37.
Mills JL, Taylor LM, Porter JMBuerger's disease in the modern era. Am J Surg154:123-129, 1987.
38.
Olin JW, Young JR, Graor RA, et al. The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation82:IV3-8, 1990.
39.
Inada K., Katsumura T.The entity of Buerger's disease. Angiology23:668-687, 1972.
40.
Adar R., Papa MZ, Halpern Z., et al. Cellular sensitivity to collagen in thromboangiitis obliterans . N Engl J Med308:1113-1116, 1983 .
41.
Hamlin E. Jr, Warren R., Kennard HEThromboangiitis obliterans. An evaluation of therapy with special reference to lumbar sympathectomy. N Engl J Med241:849-853. 1949.
42.
Hirai M., Shionoya S.Intermittent claudication in the foot and Buerger's disease. Br J Surg65:210-213, 1978.
43.
Ohta T., Shionoya S.Fate of the ischemic limb in Buerger's disease. Br J Surg75:259-262, 1988.
44.
Fiessinger JN , Schafer M.Trial of Iloprost versus aspirin treatment for critical limb ischemia of thromboangiitis obliterans. Lancet335:555-557, 1990.
45.
Stanson AWRoentgenographic findings in major vasculitic syndromes. Rheum Dis Clin North Am16:294-308, 1990.
46.
Shionoya S. , Ban I., Nakata Y., et al. Diagnosis pathology and treatment of Buerger's disease. Surgery75:695-700, 1974.
47.
Lie JJThromboangiitis obliterans (Buerger's disease) in women. Medicine65:65-72, 1986.
48.
Gulati SM, Madhra K., Thusoo TK, et al. Autoantibodies in thromboangiitis obliterans (Buerger's disease) . Angiology33:642-650, 1982.
49.
Eldrup-Jorgensen J., Flanigan P., Brace L., et al. Hypercoagulable states and lower extremity ischemia. J Vasc Surg9:333-341, 1989.
50.
Donaldson MC , Weinberg DS, Bekis M., et al. Screening for hypercoagulable states in vascular surgical practice: A preliminary study . J Vasc Surg11:825-831, 1990.
51.
Bowels CAVasculopathy associated with the antiphospholipid antibody syndrome . Rheum Dis Clin North Am16:471-490, 1990.
52.
Vira Reddi HT, Amer Nath LSNew concepts in the management of ischemic lower extremities. Int Angiol9:97-104, 1990.
53.
Hill GL, Moeliono J., Tumewu F., et al. Description of the clinical syndrome and some aspects of its aetiologyBr J Surg60:606-613, 1973.
54.
Freeman NEThe diagnosis and treatment of thromboangiitis obliterans in the vascular centers of the army general hospitals. Am Heart J33:332-340, 1947.
55.
Allen EVThromboangiitis obliterans: A clinical study of 200 cases. I. Etiology, pathology, symptoms, diagnosis. Ann Intern Med1:535-549, 1927.
56.
Abramson DI , Zayas AM, Canning JR, et al. Thromboangiitis obliterans: A true clinical entity. Am J Cardiol12:107-118, 1963.
57.
De Bakey ME , Crawford ES, Garret E., et al. Occlusive disease of the lower extremities in patients 16 to 37 years of age. Ann Surg159:873-890, 1964.
Papa MZ, Bass A., Adar R., et al. Autoimmune mechanisms in thromboangiitis obliterans (Buerger's disease): The role of tobacco antigen and the major histocompatibility complex . Surgery (in press).
70.
Powel JJSmoking and arterial disease—News of an old enemy. Eur J Vasc Surg5:227-228, 1991.
71.
Numano F., Sasazuki T., Koyama T., et al. HLA in Buerger's disease. Exp Clin Immunogenet3:195-200, 1986.
72.
Ohtawa T., Juji T., Kawano N., et al. HL-A antigen in thromboangiitis obliterans. JAMA230:1126, 1974.
73.
Smolen JS, Youngchaiyud U., Weidinger P., et al. Autoimmunological aspects of thromboangiitis obliterans (Buerger's disease). Clin Immunol Immunopathol11:168-177, 1978.
74.
Kamath MVThromboangiitis obliterans—Its overwhelming incidence in lower limbs; a plausible explanation. Angiology36:880-883, 1985.
75.
Yu HS, Sheu HM, Ko SS, et al. Studies on blackfoot disease and chronic arsenism in Southern Taiwan. J Dermatol11:361-370, 1984.
76.
Gulati SM, Singh KS, Thusoo TK, et al. Immunological studies in thromboangiitis obliterans (Buerger's disease). J Surg Res27:287-293, 1979.
77.
Gulati SM, Saha K., Kant L., et al. Significance of circulatory immune complexes in thromboangiitis obliterans (Buerger's disease). Angiology35:276-281, 1984.
78.
De Albuquerque RR, Delgado L., Correia P., et al. Circulating immune complexes in Buerger's disease—Endarteritis obliterans in young men. J Cardiovasc Surg30:821-825, 1989.